More than 200 preventive vaccines, developed by both industry and non-indus

More than 200 preventive vaccines, developed by both industry and non-industry players. (Roots Analy

steffan987
steffan987
3 min read

Technical advances, especially in the field of biotechnology, have led to the development of several next generation preventive vaccines, including recombinant vaccines, viral vector based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunological memory.

 

To order this 250+ page report, which features 85+ figures and 125+ tables, please visit this link

 

The USD 94 billion (by 2030) financial opportunity within the global preventive vaccine market has been analyzed across the following segments:

Route of Administration

IntramuscularSubcutaneousOralIntravenousOthers

Type of Vaccine

Pneumococcal Conjugate VaccineHuman Papilloma Virus VaccineRotavirus VaccineInfluenza VaccineMMR VaccineTetanus and Diphtheria Booster VaccineVaricella VaccineDTaP-Hib-IPV VaccineDTaP-HepB-Hib-IPV VaccineOthers

Type of Vaccine API

Live, Attenuated VaccineInactivated VaccineConjugate VaccineSubunit VaccineToxoid VaccineOthers

Target Patient Population

Pediatric Patients

Adults

Key Players

GlaxoSmithKline

Merck

Sanofi Pasteur

Pfizer

Emergent BioSolutions

CSL

Others

Key Geographical Regions

North America

Europe

Asia Pacific

Rest of the World

 

The Global Preventive Vaccines Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: 

Bio Farma

Emergent BioSolutions

GC Pharma

GlaxoSmithKline

Janssen

Merck

Novavax

Pfizer

Sanofi Pasteur

Valneva

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Market Landscape

5. Company Competitiveness Analysis

6. Company Profiles

7. Clinical Trial Analysis

8. Ongoing Vaccine Development Initiatives for Complex Conditions

9. Funding and Investment Analysis

10. Market Sizing and Opportunity Analysis

11. Case-in-Point: Contract Manufacturing of Vaccines

12. Concluding Remarks

13. Executive Insights

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]  

Discussion (0 comments)

0 comments

No comments yet. Be the first!